<DOC>
	<DOCNO>NCT01607892</DOCNO>
	<brief_summary>The purpose research study find information relate high dose KCP-330 give safely side effect may cause , examine body affect KCP-330 concentration blood ( pharmacokinetics PK ) , examine effect KCP-330 body ( pharmacodynamics PDn ) obtain information effectiveness treat cancer .</brief_summary>
	<brief_title>Safety Study Selective Inhibitor Nuclear Export ( SINE ) KPT-330 Patients With Advanced Hematological Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Malignancies refractory intolerant establish therapy know provide clinical benefit . Patients must candidate antitumor regime know provide clinical benefit . 2 . All patient must evidence progressive disease study entry.Previously untreated patient chemotherapy candidate Arm 2 may advance disease ( without clear progression ) . There upper limit number prior treatment provide inclusion criterion meet exclusion criterion meet . Exclusion Criteria 1 . Radiation , chemotherapy , immunotherapy anticancer therapy ≤2 week prior cycle 1 day 1 mitomycin C radioimmunotherapy 6 week prior cycle 1 day 1 . 2 . Patients active graft versus host disease allogeneic stem cell transplantation . At least 3 month must elapse since completion allogeneic stem cell transplantation except patient AML , least 2 month must elapse ; 3 . Known active hepatitis A , B , C infection ; know positive HCV RNA HBsAg ( HBV surface antigen ) ; 4 . Patients active CNS malignancy . Asymptomatic small lesion consider active . Treated lesion may consider inactive stable least 3 month . Patient malignant cell cerebrospinal fluid ( CSF ) without CNS symptom may include . 5 . Significantly diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea . 6 . Grade ≥2 peripheral neuropathy baseline ( within 14 day prior cycle 1 day 1 ) . 7 . Macular degeneration , uncontrolled glaucoma , markedly decrease visual acuity . 8 . In opinion investigator , patient significantly ideal body weight .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>non-Hodgkin Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Waldenström 's macroglobulinemia</keyword>
	<keyword>Peripheral T-Cell Lymphoma</keyword>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
	<keyword>Chronic Myelocytic Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>